Log In

Forgot Password?


Not a member? Continue as a nonmember.

Become a Member

By becoming a member of the AAN, you can receive exclusive information to help you at every stage of your career. Benefits include:

Join Now See All Benefits

Loading... please wait

Abstract Details

In depth analysis of T cells in multiple sclerosis patients after treatment with Cladribine
Multiple Sclerosis
P6 - Poster Session 6 (12:00 PM-1:00 PM)

Cladribine is an orally bioavailable purine analog that is rapidly taken up by lymphocytes. It is thought to work as a disease-modifying therapy in relapse-remitting MS by depleting autoreactive T and B cells.

Investigate the T cell repertoire within relapse-remitting multiple sclerosis (MS) patients after treatment with cladribine.

Peripheral blood mononuclear cells from MS patients before and 6 months after Cladribine treatment were stained with our panel of 40 isotope-conjugated antibodies. Mass cytometry, which combines flow cytometry with mass spectrometry, was then used to analyse and phenotype T cell subsets with unparalleled depth.

Our results show that Cladribine-induced remission is associated with shifts within the T cell repertoire, particularly CD8+ T cells. This included an increase in CD8+ effector memory RA+ and CD8+ effector memory T cells, with a decrease in CD8+ naïve T cells.

Mass cytometry has provided us with unparalleled levels of detail to determine which T cell subsets are affected by Cladribine treatment. These studies will allow us to track efficacy and design new ways of targeting these T cells more specifically.

Felix Marsh-Wakefield
No disclosure on file
Simon Hawke No disclosure on file
Georges Grau No disclosure on file
Pierre Juillard No disclosure on file
Thomas Ashhurst No disclosure on file
Helen McGuire No disclosure on file
Scott N Byrne No disclosure on file